V

Viridian Therapeutics
D

VRDN

21.375
USD
0.41
(1.96%)
مغلق
حجم التداول
24,896
الربح لكل سهم
-4
العائد الربحي
-
P/E
-6
حجم السوق
1,745,533,137
أصول ذات صلة الأخبار المقالات

العنوان: Viridian Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly knownas VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).